Kingdom2Music Brings Artist's CustomScored Tracks OnlineLOS ANGELES Jan

Conjunctivitis is the reason for over 4 million visits a year to doctors andemergency rooms in the United States. NovaBay believes that the currentworldwide market for products prescribed for bacterial conjunctivitis isapproximately $1 billion. There is no specific treatment for viralconjunctivitis, which can take from seven days to three weeks or longer to clearon its own. Bacterial conjunctivitis is frequently treated with antibiotics, although the leading products are reported to be encounteringincreasing antibiotic resistance. NVC-422has been shown, in-vitro, to be effective against bacteria of all types,including multidrug resistant species, against shedding viruses, includingadenoviruses and herpes viruses and against yeasts and fungi. It has been shown tobe safe, in-vivo, at expected therapeutic doses in the nose, bladder, wounds andeye. It is a stable analog of an anti-infective molecule produced by mammalianwhite blood cells NVC-422 is protected by U.S Patent 7,462,361 until 2026.

In addition to Alcons development in the eye, NovaBay has taken NVC-422 intoPhase II human trials for infections in the nose and bladder and expects tobegin a Phase II trial for the treatment of skin infections, including thosecaused by MRSA, in 2009 About NovaBay PharmaceuticalsNovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused ondeveloping innovative non-antibiotic, antimicrobial product candidates targetingthe treatment or prevention of a wide range of infections in hospital andnon-hospital environments. NovaBay has discovered and is developing a class ofnon-antibiotic anti-infective compounds, which it has named Aganocide compounds,which are based upon small molecules that are generated by white blood cellsthat defend the body against invading pathogens, without ever developingresistance. NovaBay believes that Aganocide compounds could form a platform onwhich to create a variety of products to address differing needs in thetreatment and prevention of bacterial and viral infections, including resistantbacteria such as MRSA.

NovaBay has entered into a licensing and researchcollaboration agreement with an affiliate of Alcon, Inc. NovaBay and Aganocide are registered trademarks of NovaBay Pharmaceuticals,Inc. All other trademarks and trade names are the property of their respectiveowners. Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the "safeharbor" provisions of the Private Securities Litigation Reform Act of 1995,based upon managements current expectations, assumptions, estimates,projections and beliefs. Factors that might cause or contribute to such differences include,but are not limited to, risks and uncertainties relating to difficulties ordelays in discovery, development, testing, regulatory approval, production andmarketing of the companys product candidates, unexpected adverse side effectsor inadequate therapeutic efficacy of the product candidates, the uncertainty ofpatent protection for the companys intellectual property or trade secrets, thecompanys ability to obtain additional financing as necessary and unanticipatedresearch and development and other costs and other risks detailed from time totime in NovaBays filings with the Securities and Exchange Commission includingthe annual report on Form 10-K for the year ended December 31, 2007.

Theforward-looking statements in this release speak only as of this date, andNovaBay disclaims any intent or obligation to revise or update publicly anyforward-looking statement except as required by law. NovaBay Pharmaceuticals, Inc.Investor Relations:Theresa Granados, 510-899-8870Head of Investor orThe Investor Relations GroupInvestor Relations:Adam Holdsworth / James CarbonaraMedia Relations:Janet Vasquez / Laura Colontrelle212-825-3210 Copyright Business Wire 2009. Kingdom2Music Brings Artist's Custom-Scored Tracks OnlineLOS ANGELES, Jan. 13 /PRNewswire/ The words "day job" aren't generallythe mark of success for a musician. Except in the case of artist/composerGooding, whose day job is reinventing the music licensing industry by bringinghigh-impact tracks to the world via the online catalog Kingdom2Music With a mission to pair perfect music with; film, television, advertising,commercial video, video games, Web sites, branding, or any creative project,Kingdom2 fulfills by cataloging 20 plus years of Gooding's original scoresonline making custom-quality tracks one click away for busy and music hungryprofessionals."It isn't our goal to be the biggest catalog or to mimic work that'salready been done," said Gooding, founder of Kingdom2.